BofA lowered the firm’s price target on Danaher (DHR) to $220 from $230 and keeps a Buy rating on the shares. While there has been some stabilization and/or improvement in some areas of Life Sciences and Diagnostic Tools, several pockets of uncertainty and softness over the past year remain and are likely to persist for at least the next few quarters, says the analyst, who is trimming forecasts for many core Tools companies and now anticipates a more gradual return to “normal.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DHR:
- Danaher Updates By-laws and Launches Share Buyback
- A10 Networks CFO Brian Becker to step down, Michelle Caron to succeed
- Danaher price target lowered to $241 from $250 at RBC Capital
- Third Point boosts position in Nvidia, takes new stakes in Mr Cooper, Meta
- UnitedHealth Stock (UNH) Tumbles 50% YTD; Here’s How to Buy the Dip Without the Risk